Q-omics provides the consensus-scored GTF2H2 profile across patient tissues and cancer cell-line models. GTF2H2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, GTF2H2 is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, GTF2H2 RNA expression shows 14,678 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, and UVM as cancer lineages where GTF2H2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTF2H2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTF2H2 survival associations across molecular data types. GTF2H2 RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTF2H2 RNA expression–survival associations across cancer types. High GTF2H2 expression shows unfavorable associations in KICH, MESO, KIRP and LIHC, but favorable associations in OV and DLBC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for GTF2H2 RNA expression.
This table summarizes GTF2H2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GTF2H2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTF2H2 shows lower tumor expression in KICH, KIRC and THCA and higher tumor expression in LIHC, STAD and CHOL. The KICH box plot shows higher GTF2H2 RNA expression in normal versus tumor tissue (log2 FC = −0.931, t-test p < 0.001).
This table shows molecular features associated with GTF2H2 in patient tissues and cancer cell lines. In patient samples, GTF2H2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GTF2H2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
